Alcohol-associated Liver Disease

Questions discussed in this category

This is based on the recent publication by Bernstein et al., PMID 38551564 which investigated the increased rate of initiation of MAUD in the hospital...

5 Answers available

Is there a role for use of GLP-1/GIP receptor agonists in the management of substance use disorders, whether or not they meet other inclusion criteria for their use?

2 Answers available

Papers discussed in this category

Scientific reports, 2023 Nov 28

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.

JCI insight, 2023 Jun 22

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.

Drug and alcohol dependence, 2024 Sep 07

Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

JAMA psychiatry, 2025 Apr 01

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.

Alcohol-associated Liver Disease

Questions discussed in this category

Papers discussed in this category

Related Topics